Abstract
An overview how to measure and to quantify radiolysis by the addition of quenchers and to maintain Radio- Chemical Purity (RCP) of vulnerable methionine-containing regulatory peptides is presented. High RCP was only achieved with a combination of quenchers. However, quantification of RCP is not standardized, and therefore comparison of radiolabelling and RCP of regulatory peptides between different HPLC-systems and between laboratories is cumbersome. Therefore we suggest a set of standardized requirements to quantify RCP by HPLC for radiolabelled DTPA- or DOTA-peptides. Moreover, a dosimetry model was developed to calculate the doses in the reaction vials during radiolabelling and storage of the radiopeptides, and to predict RCP in the presence and absence of quenchers. RCP was measured by HPLC, and a relation between radiation dose and radiolysis of RCP was established. The here described quenchers are tested individually as ƒ(concentration) to investigate efficacy to reduce radiolysis of radiolabelled methionine-containing regulatory peptides.
Keywords: gastrin releasing peptide, HPLC, minigastrin, quenchers, radiochemical purity, radiolysis, methionine, regulatory peptides
Current Topics in Medicinal Chemistry
Title:Effectiveness of Quenchers to Reduce Radiolysis of 111In- or 177Lu-Labelled Methionine-Containing Regulatory Peptides. Maintaining Radiochemical Purity as Measured by HPLC
Volume: 12 Issue: 23
Author(s): Erik de Blois, Ho Sze Chan, Mark Konijnenberg, Rory de Zanger and Wouter A.P. Breeman
Affiliation:
Keywords: gastrin releasing peptide, HPLC, minigastrin, quenchers, radiochemical purity, radiolysis, methionine, regulatory peptides
Abstract: An overview how to measure and to quantify radiolysis by the addition of quenchers and to maintain Radio- Chemical Purity (RCP) of vulnerable methionine-containing regulatory peptides is presented. High RCP was only achieved with a combination of quenchers. However, quantification of RCP is not standardized, and therefore comparison of radiolabelling and RCP of regulatory peptides between different HPLC-systems and between laboratories is cumbersome. Therefore we suggest a set of standardized requirements to quantify RCP by HPLC for radiolabelled DTPA- or DOTA-peptides. Moreover, a dosimetry model was developed to calculate the doses in the reaction vials during radiolabelling and storage of the radiopeptides, and to predict RCP in the presence and absence of quenchers. RCP was measured by HPLC, and a relation between radiation dose and radiolysis of RCP was established. The here described quenchers are tested individually as ƒ(concentration) to investigate efficacy to reduce radiolysis of radiolabelled methionine-containing regulatory peptides.
Export Options
About this article
Cite this article as:
de Blois Erik, Sze Chan Ho, Konijnenberg Mark, de Zanger Rory and A.P. Breeman Wouter, Effectiveness of Quenchers to Reduce Radiolysis of 111In- or 177Lu-Labelled Methionine-Containing Regulatory Peptides. Maintaining Radiochemical Purity as Measured by HPLC, Current Topics in Medicinal Chemistry 2012; 12 (23) . https://dx.doi.org/10.2174/1568026611212230005
DOI https://dx.doi.org/10.2174/1568026611212230005 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Guide for Selection of Relevant Cell Lines During the Evaluation of new Anti-Cancer Compounds
Anti-Cancer Agents in Medicinal Chemistry Cytotoxic Activity and Inhibition of Tumor Cell Invasion by Derivatives of a Chemically Modified Tetracycline CMT-3 (COL-3)
Current Medicinal Chemistry The Regulation of miRNAs in Inflammation-Related Carcinogenesis
Current Pharmaceutical Design ADAM17 as a Therapeutic Target in Multiple Diseases
Current Pharmaceutical Design Targeting Drugs to APJ Receptor: The Prospect of Treatment of Hypertension and Other Cardiovascular Diseases
Current Drug Targets The Epidemiological, Mechanistic and Potential Clinical Role of Androgen Receptor (AR) in Urothelial Carcinoma
Current Drug Targets The Control of Cell Cycle in Mouse Primordial Germ Cells: Old and New Players
Current Pharmaceutical Design AKT and cytosolic phospholipase A<sub>2</sub>α form a positive loop in prostate cancer cells
Current Cancer Drug Targets ADAM Metalloproteinases as Potential Drug Targets
Current Medicinal Chemistry The Immunological Side-Effects of Sedative Agents in the Intensive Care Unit
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Synthesis and Biological Properties of Dihydro-Oxadiazine-Based Heterocyclic Derivatives
Mini-Reviews in Medicinal Chemistry Synthesis and Cytotoxic Activities of a Curcumin Analogue and Its bis- Mannich Derivatives
Letters in Drug Design & Discovery Bisphosphonates as Treatment of Bone Metastases
Current Pharmaceutical Design Applications of High Content Screening in Life Science Research
Combinatorial Chemistry & High Throughput Screening Comparison of the Inhibitory Effects of Clotrimazole and Ketoconazole against Human Carboxylesterase 2
Current Drug Metabolism Differential Involvement of Myosin II and VI in the Spontaneous and SDF- 1-induced Migration of Adult CD133+ Hematopoietic Stem/Progenitor Cells and Leukemic Cells
Current Cancer Therapy Reviews Extracellular Vesicles as Novel Delivery Tools for Cancer Treatment
Current Cancer Drug Targets Estrogen Receptors as Therapeutic Targets in Breast Cancer
Current Topics in Medicinal Chemistry Strategies for Effective Naked-DNA Vaccination Against Infectious Diseases
Recent Patents on Anti-Infective Drug Discovery Targets for Anti-metastatic Drug Development
Current Pharmaceutical Design